Labcorp (NYSE:LH) Updates FY 2026 Earnings Guidance

Key Points

• Labcorp issued FY 2026 guidance of $18.10–$18.55 in EPS and $14.7–$14.8 billion in revenue, broadly in line with Wall Street estimates.
• Analysts remain generally positive, with nine Buy ratings and three Holds, producing a “Moderate Buy” consensus and an average price target of $336.36.
• Labcorp reported quarterly results above expectations, including $4.99 EPS and $3.73 billion in revenue, while maintaining a quarterly dividend of $0.72 per share.

Labcorp (NYSE:LH - Get Free Report) issued an update on its FY 2026 earnings guidance on Friday. The company provided EPS guidance of 18.100-18.550 for the period, compared to the consensus estimate of 18.340. The company issued revenue guidance of $14.7 billion-$14.8 billion, compared to the consensus revenue estimate of $14.7 billion.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on LH shares. Wall Street Zen upgraded shares of Labcorp from a "hold" rating to a "buy" rating in a research report on Sunday, July 12th. Morgan Stanley upped their price target on shares of Labcorp from $308.00 to $338.00 and gave the company an "overweight" rating in a research report on Friday, July 31st. Bank of America lifted their price target on shares of Labcorp from $300.00 to $320.00 and gave the stock a "buy" rating in a report on Monday, July 13th. UBS Group boosted their price objective on shares of Labcorp from $361.00 to $380.00 and gave the stock a "buy" rating in a research note on Friday, September 11th. Finally, Truist Financial raised their target price on Labcorp from $320.00 to $350.00 and gave the stock a "buy" rating in a research report on Friday, July 31st. Nine analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $336.36.

Labcorp Price Performance

Shares of NYSE LH opened at $323.04 on Friday. The firm has a market capitalization of $26.20 billion, a P/E ratio of 26.72, a P/E/G ratio of 1.84 and a beta of 0.88. The firm's 50-day moving average price is $313.65 and its 200-day moving average price is $282.90. The company has a current ratio of 1.80, a quick ratio of 1.53 and a debt-to-equity ratio of 0.69. Labcorp has a 1-year low of $244.52 and a 1-year high of $341.80.

Labcorp (NYSE:LH - Get Free Report) last issued its earnings results on Thursday, July 30th. The medical research company reported $4.99 EPS for the quarter, beating the consensus estimate of $4.78 by $0.21. Labcorp had a return on equity of 16.74% and a net margin of 6.99%.The company had revenue of $3.73 billion during the quarter, compared to the consensus estimate of $3.71 billion. During the same period last year, the business posted $4.35 EPS. The firm's revenue for the quarter was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Equities research analysts anticipate that Labcorp will post 18.32 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 28th were issued a dividend of $0.72 per share. The ex-dividend date was Friday, August 28th. This represents a $2.88 annualized dividend and a dividend yield of 0.9%. Labcorp's payout ratio is currently 23.82%.

Insider Activity at Labcorp

In related news, Director Kerrii B. Anderson sold 3,000 shares of Labcorp stock in a transaction on Monday, August 17th. The shares were sold at an average price of $318.02, for a total value of $954,060.00. Following the completion of the sale, the director owned 6,563 shares of the company's stock, valued at approximately $2,087,165.26. This trade represents a 31.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Kathryn W. Kyle sold 92 shares of the business's stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total transaction of $26,329.48. Following the sale, the executive vice president owned 3,904 shares of the company's stock, valued at $1,117,285.76. This trade represents a 2.30% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 8,919 shares of company stock valued at $2,826,593 over the last three months. 0.84% of the stock is currently owned by company insiders.

About Labcorp

Labcorp NYSE: LH, formerly Laboratory Corporation of America Holdings, is a global life sciences and laboratory services company headquartered in Burlington, North Carolina. The company provides diagnostic testing and related services to physicians, hospitals, health systems, employers, government agencies and consumers.

Its diagnostics business offers routine and specialty laboratory testing, including molecular, genetic, oncology, women's health, infectious disease and pathology services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.